MX2012003214A - Composiciones de enzima pancreatica y metodos para tratar pancreatitis e insuficiencia pancreatica. - Google Patents

Composiciones de enzima pancreatica y metodos para tratar pancreatitis e insuficiencia pancreatica.

Info

Publication number
MX2012003214A
MX2012003214A MX2012003214A MX2012003214A MX2012003214A MX 2012003214 A MX2012003214 A MX 2012003214A MX 2012003214 A MX2012003214 A MX 2012003214A MX 2012003214 A MX2012003214 A MX 2012003214A MX 2012003214 A MX2012003214 A MX 2012003214A
Authority
MX
Mexico
Prior art keywords
pancreatic
methods
enzyme compositions
treating pancreatitis
insufficiency
Prior art date
Application number
MX2012003214A
Other languages
English (en)
Spanish (es)
Inventor
Gopi M Venkatesh
Stephen Perrett
Ruth Thieroff-Ekerdt
Konstantino Efthymiopoulos
Original Assignee
Aptalis Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43730817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012003214(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptalis Pharmatech Inc filed Critical Aptalis Pharmatech Inc
Publication of MX2012003214A publication Critical patent/MX2012003214A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2012003214A 2009-09-17 2010-09-17 Composiciones de enzima pancreatica y metodos para tratar pancreatitis e insuficiencia pancreatica. MX2012003214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24346709P 2009-09-17 2009-09-17
PCT/US2010/049203 WO2011035079A1 (en) 2009-09-17 2010-09-17 Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency

Publications (1)

Publication Number Publication Date
MX2012003214A true MX2012003214A (es) 2012-08-01

Family

ID=43730817

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003214A MX2012003214A (es) 2009-09-17 2010-09-17 Composiciones de enzima pancreatica y metodos para tratar pancreatitis e insuficiencia pancreatica.

Country Status (23)

Country Link
US (2) US8784884B2 (enExample)
EP (1) EP2477645B1 (enExample)
JP (1) JP5877399B2 (enExample)
KR (1) KR101771752B1 (enExample)
CN (2) CN102630164B (enExample)
AR (1) AR078291A1 (enExample)
AU (1) AU2010295494B2 (enExample)
BR (1) BR112012005837A8 (enExample)
CA (1) CA2774269C (enExample)
CL (1) CL2012000658A1 (enExample)
CO (1) CO6531419A2 (enExample)
ES (1) ES2690661T3 (enExample)
HK (1) HK1218886A1 (enExample)
IL (2) IL218656A (enExample)
MX (1) MX2012003214A (enExample)
MY (1) MY161843A (enExample)
NZ (1) NZ599143A (enExample)
RU (1) RU2570376C2 (enExample)
SA (1) SA110310695B1 (enExample)
TW (2) TW201639545A (enExample)
UY (1) UY32896A (enExample)
WO (1) WO2011035079A1 (enExample)
ZA (1) ZA201202761B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
EP2079445B1 (en) 2007-02-20 2015-11-04 Aptalis Pharma Limited Stable digestive enzyme compositions
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
EP2621476B8 (en) * 2010-10-01 2020-12-23 Société des Produits Nestlé S.A. Enteric coated, low-strength pancrelipase formulations
RU2602183C2 (ru) * 2011-08-08 2016-11-10 Апталис Фарма Лтд. Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
WO2015020943A2 (en) 2013-08-09 2015-02-12 Aptalis Pharma Ltd. Digestive enzyme composition suitable for enteral administration
FR3079146B1 (fr) * 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
WO2021202363A1 (en) * 2020-03-30 2021-10-07 Wall Jai Combined animal-derived and synthetically produced pancreatic enzyme replacement therapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4447412A (en) 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5460812A (en) 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
DE69728857T3 (de) 1996-02-09 2010-02-18 Quadrant Drug Delivery Ltd., Ruddington Feste arzneimittel enthaltend trehalose
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
CN1156308C (zh) * 2002-04-19 2004-07-07 北京世诺医药科技有限公司 多酶组合胶囊
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
EP1596838A2 (en) 2003-02-11 2005-11-23 Torrent Pharmaceuticals Ltd Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
AU2004285558A1 (en) * 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (CCK) concentration and for treating pain
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
DE602005009677D1 (de) 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
DK1755656T3 (da) * 2004-05-24 2010-10-04 Novozymes As Enzymer til farmaceutisk anvendelse
HUE031245T2 (en) 2004-10-14 2017-06-28 Lilly Co Eli Preparations containing lipase, protease and amylase for the treatment of pancreatic insufficiency
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CA2612648A1 (en) * 2005-06-24 2006-12-28 Novozymes A/S Lipases for pharmaceutical use
US20070025977A1 (en) 2005-07-21 2007-02-01 Mulberg Andrew E Method of treating steatorrhea in infants
MX2008000850A (es) 2005-07-29 2008-03-18 Solvay Pharm Gmbh Procedimientos para la fabricacion de polvo de pancreatina esterilizada.
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US8071089B2 (en) 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
MY147954A (en) * 2006-05-26 2013-02-15 Nestec Sa Methods of use and nutritional compositions of touchi extract
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
US20090117180A1 (en) 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
EP2079445B1 (en) 2007-02-20 2015-11-04 Aptalis Pharma Limited Stable digestive enzyme compositions
US20110171294A1 (en) 2008-09-30 2011-07-14 Dsm Ip Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency

Also Published As

Publication number Publication date
CN102630164A (zh) 2012-08-08
EP2477645B1 (en) 2018-08-15
TWI572372B (zh) 2017-03-01
IL245875A0 (en) 2016-07-31
US8784884B2 (en) 2014-07-22
CA2774269C (en) 2017-03-21
KR101771752B1 (ko) 2017-08-25
RU2570376C2 (ru) 2015-12-10
MY161843A (en) 2017-05-15
BR112012005837A2 (pt) 2017-05-30
SA110310695B1 (ar) 2014-11-26
US20140287035A1 (en) 2014-09-25
HK1218886A1 (zh) 2017-03-17
NZ599143A (en) 2014-05-30
AU2010295494A1 (en) 2012-03-29
IL218656A (en) 2017-12-31
EP2477645A1 (en) 2012-07-25
RU2012113253A (ru) 2013-10-27
IL218656A0 (en) 2012-05-31
CA2774269A1 (en) 2011-03-24
US20110064799A1 (en) 2011-03-17
JP5877399B2 (ja) 2016-03-08
CO6531419A2 (es) 2012-09-28
UY32896A (es) 2011-02-28
CN102630164B (zh) 2015-09-16
WO2011035079A1 (en) 2011-03-24
JP2013505255A (ja) 2013-02-14
ZA201202761B (en) 2012-12-27
AR078291A1 (es) 2011-10-26
TW201113052A (en) 2011-04-16
ES2690661T3 (es) 2018-11-21
EP2477645A4 (en) 2014-06-25
KR20120100915A (ko) 2012-09-12
AU2010295494B2 (en) 2014-09-25
CL2012000658A1 (es) 2012-09-28
CN105214073A (zh) 2016-01-06
US20160051472A9 (en) 2016-02-25
TW201639545A (zh) 2016-11-16
BR112012005837A8 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
MY161843A (en) Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
PH12020550450A1 (en) Certain chemical entities, compositions and methods
IL235342B (en) Using hsp70 as a regulator of enzymatic activity
WO2011140202A3 (en) Mif modulators
GB2511713A (en) Methods of treating behavioral symptoms of neurological and mental disorders
PH12015502362A1 (en) Certain chemical entities, compositions and methods
WO2010021693A3 (en) Mif modulators
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
GB201320528D0 (en) Enzyme delivery systems and methods of preparations and use
WO2008067121A3 (en) Methods of treating cognitive impairment and dementia
ZA201100133B (en) Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
MX2009011215A (es) Derivados de triazolopiridina carboxamida, su preparacion y su aplicacion terapeutica.
WO2011075606A3 (en) Hyperglycosylated polypeptide variants and methods of use
IN2012DN00592A (enExample)
WO2011008947A3 (en) Treatment and diagnosis of immune disorders
IL207943A0 (en) Modulation of enzymatic structure, activity, and/or expression level
WO2011116351A3 (en) Methods and compositions for the treatment of cancer
PH12014500304A1 (en) Enzyme system
MX2012004617A (es) Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago.
MX2012001875A (es) Proceso para la preparación de inhibidores de la catepsina s.
GB0518921D0 (en) Enzymatic composition and method of textile treatment
SG10201405791XA (en) Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
UA45384U (ru) Средство для лечения альвеолита у пациентов с вирусной этиологией заболевания
WO2009053895A3 (en) Quinoline urotensin-ii receptor antagonists
UA51067U (ru) Способ лечения гнойных ран

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: APTALIS PHARMA LIMITED

FG Grant or registration